Glytec receives Notice of Allowance from U.S. Patent and Trademark Office.
+ Regulatory
Jamie Barrand | Oct 14, 2015

Glytec receives Notice of Allowance from U.S. Patent and Trademark Office

The U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application from Glytec for key aspects of the company's core technology for diabetes management; Glytec is an innovator in the field of glucose management software, and the Notice of Allowance is for a system for glycemic control of a diabetic patient that includes a smartphone-based diabetes mobile application.

The app will allow patients access to real-time insulin dosing advice, the goal of which is to stabilize and maintain blood glucose levels within a prescribed range.

The app will also provide advice about unexpected glycemic episodes and alert a provider if further intervention is needed.

“At Glytec, each and every employee is focused on a critical mission -- to improve the lives of people with diabetes,” Glytec Chief Medical Officer Andrew S. Rhinehart, M.D., said. “Our solutions have successfully helped clinicians improve inpatient outcomes and reduce hospital readmissions via precise glucose management, and a mobile app that helps patients better control their glucose levels in their day-to-day lives will be a high-impact addition to our diabetes management platform.”

Bob Leonard, president and CEO of Glytec, agreed.

“The shift to value-based payments and the development of innovative population health models along with the growth of EHRs and the emergence of smart, connected devices are collectively ushering in the era of data-driven care management," he said.

Organizations in this story

+ Glytec

More News